Key result
Treated or high-grade rejection linked to ~6-fold higher 7-year risk of allograft loss or CAV.
Why the study?
Interstitial myocardial fibrosis in transplanted hearts and the collagen profile have not been fully characterized, particularly regarding the effects of cyclosporine and rejection episodes.
Cohort (n=650)
No
Absolute Event Rate: 32.9% vs 5.1%
p-value: p=<0.001
No takes yet. Share an insight, caveat, or question.
May warrant closer surveillance in heart transplant recipients with rejection history; leaves open whether targeted interventions improve allograft outcomes.
Tazelaar et al. (1990) conducted a cohort in Cardiac allograft rejection (n=650). Historical treated or high-grade rejection vs. Controls (no historical inflammatory events) was evaluated on Composite of allograft loss (cardiovascular death or retransplantation) or ≥grade 2 cardiac allograft vasculopathy (CAV) at 7 years (p=<0.001). A history of treated or high-grade rejection was associated with a significantly higher 7-year risk of allograft loss or severe cardiac allograft vasculopathy compared to controls (32.9% vs 5.1%, p<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: